Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

New regimens based on 2 or more novel agents are sought to shorten or to simplify treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the novel combinations of bedaquiline (BDQ) plus pretomanid (PMD) plus pyrazinamide (PZA) and PMD plus moxifloxacin (MXF) plus P...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Si-Yang, Tasneen, Rokeya, Tyagi, Sandeep, Soni, Heena, Converse, Paul J., Mdluli, Khisimuzi, Nuermberger, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571308/
https://www.ncbi.nlm.nih.gov/pubmed/28630203
http://dx.doi.org/10.1128/AAC.00913-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571308/
https://www.ncbi.nlm.nih.gov/pubmed/28630203
http://dx.doi.org/10.1128/AAC.00913-17

Ejemplares similares